SCHEMBL20115564

SCHEMBL20115564

CC(C)(C)OC(=O)NCC12CCOC1OCC2

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HCRTR2 O43614 1/20 0.50
EPHX1 P07099 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
GAA P10253 2/20 0.36
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA9 Q16790 2/20 0.35
DRD2 P14416 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
CACNA1H O95180 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8925642 0.80 HCRTR2 (0.44) HCRTR2EPHX1TDP1MEN1KMT2A
SCHEMBL22532010 0.72 HCRTR2 (0.42) HCRTR2EPHX1TDP1MEN1KMT2A
SCHEMBL21937632 0.72 HCRTR2 (0.49) HCRTR2EPHX1TDP1MEN1KMT2A
SCHEMBL13641704 0.72 HCRTR2 (0.48) HCRTR2EPHX1TDP1MEN1KMT2A
SCHEMBL15497076 0.72 HCRTR2 (0.44) HCRTR2EPHX1TDP1MEN1KMT2A
SCHEMBL25557844 0.72 HCRTR2 (0.43) HCRTR2EPHX1TDP1MEN1KMT2A
SCHEMBL29945849 0.71 HCRTR2 (0.42) HCRTR2EPHX1TDP1MEN1KMT2A
SCHEMBL18415409 0.71 HCRTR2 (0.58) HCRTR2EPHX1TDP1MEN1KMT2A
SCHEMBL16846897 0.71 HCRTR2 (0.45) HCRTR2EPHX1TDP1MEN1KMT2A
SCHEMBL23070850 0.71 HCRTR2 (0.40) HCRTR2EPHX1TDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3532462-B1 ACYL SULFONAMIDE NAV1.7 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-10-13 EP disclosed
US-10836758-B2 Acyl sulfonamide NaV1.7 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2020-11-17 US disclosed
US-20200048240-A1 ACYL SULFONAMIDE NAV1.7 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-02-13 US disclosed
WO-2018081384-A1 ACYL SULFONAMIDE NAV1.7 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10836758-B2 Acyl sulfonamide NaV1.7 inhibitors SCN7A, SCN1A, SCN8A HCRTR2 1842/4885EPHX1 3847/4885TDP1 2450/4885
US-20200048240-A1 ACYL SULFONAMIDE NAV1.7 INHIBITORS SCN7A, SCN1A, SCN8A HCRTR2 1842/4885EPHX1 3847/4885TDP1 2450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.